- Home
- MOVE vs APVO Comparison
MOVE vs APVO Comparison
Compare MOVE & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOVE
- APVO
- Stock Information
- Founded
- MOVE 2018
- APVO 2016
- Country
- MOVE United States
- APVO United States
- Employees
- MOVE N/A
- APVO N/A
- Industry
- MOVE Biotechnology: Electromedical & Electrotherapeutic Apparatus
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- MOVE Health Care
- APVO Health Care
- Exchange
- MOVE Nasdaq
- APVO Nasdaq
- Market Cap
- MOVE 4.7M
- APVO 4.1M
- IPO Year
- MOVE 2021
- APVO N/A
- Fundamental
- Price
- MOVE $0.77
- APVO $3.06
- Analyst Decision
- MOVE Buy
- APVO Strong Buy
- Analyst Count
- MOVE 1
- APVO 1
- Target Price
- MOVE $30.00
- APVO $5,920.00
- AVG Volume (30 Days)
- MOVE 1.3M
- APVO 191.0K
- Earning Date
- MOVE 08-13-2025
- APVO 08-07-2025
- Dividend Yield
- MOVE N/A
- APVO N/A
- EPS Growth
- MOVE N/A
- APVO N/A
- EPS
- MOVE N/A
- APVO N/A
- Revenue
- MOVE $1,013,000.00
- APVO N/A
- Revenue This Year
- MOVE $1,460.71
- APVO N/A
- Revenue Next Year
- MOVE $96.77
- APVO N/A
- P/E Ratio
- MOVE N/A
- APVO N/A
- Revenue Growth
- MOVE N/A
- APVO N/A
- 52 Week Low
- MOVE $0.51
- APVO $2.81
- 52 Week High
- MOVE $6.97
- APVO $381.10
- Technical
- Relative Strength Index (RSI)
- MOVE 55.19
- APVO 38.28
- Support Level
- MOVE $0.68
- APVO $3.01
- Resistance Level
- MOVE $0.78
- APVO $3.18
- Average True Range (ATR)
- MOVE 0.09
- APVO 0.16
- MACD
- MOVE 0.02
- APVO 0.19
- Stochastic Oscillator
- MOVE 89.47
- APVO 45.45
About MOVE Movano Inc.
Movano Inc is developing a platform to deliver purpose-driven healthcare solutions to bring medical-grade, high-quality data to the forefront of consumer health devices. its initial commercial product in development is the Evie Ring, a wearable designed specifically for women. The Evie Ring combines health and wellness metrics to give a full picture of one's health, which includes resting heart rate, heart rate variability (HRV), blood oxygen saturation (SpO2), respiration rate, skin temperature variability, period and ovulation tracking, menstrual symptom tracking, activity profile, including steps, active minutes and calories burned, sleep stages and duration, and mood tracking.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.